Screener
Viridian Therapeutics, Inc. VRDN Accrued outsourced manufacturing
Accrued outsourced manufacturing at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept vrdn:AccruedOutsourcedManufacturingCurrent.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accrued compensation and related benefits | $14,170 | $19,657 |
| Accrued outsourced manufacturing | 12,624 | 15,987 |
| Accrued milestone payment | 10,000 | 10,000 |
| Accrued professional fees | 9,439 | 3,827 |
| Accrued outsourced clinical and nonclinical studies | 6,619 | 8,595 |
| Operating lease liabilities, short-term | 722 | 753 |
| Accrued interest payable | 595 | 385 |
| Other accrued liabilities | 792 | 2,442 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s accrued outsourced manufacturing?
- Viridian Therapeutics, Inc. (VRDN) reported accrued outsourced manufacturing of $12.62M in Q2 2026.
- What does accrued outsourced manufacturing mean?
- Accrued outsourced manufacturing as reported by Viridian Therapeutics, Inc. Common Stock.
Ask your AI about Viridian Therapeutics, Inc.'s accrued outsourced manufacturing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude